Last reviewed · How we verify
Early receiving G-CSF group
Early receiving G-CSF group is a Cytokine; Hematopoietic growth factor Small molecule drug developed by Department of Medical Services Ministry of Public Health of Thailand. It is currently FDA-approved for Prevention of chemotherapy-induced neutropenia in cancer patients receiving myelosuppressive chemotherapy, Mobilization of peripheral blood progenitor cells for stem cell transplantation.
G-CSF (granulocyte colony-stimulating factor) stimulates the bone marrow to produce and release neutrophils into the bloodstream to increase white blood cell counts.
Early receiving G-CSF group is associated with the treatment of Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) in adult patients. G-CSF is used as a component in the treatment regimen, specifically in the context of a double induction therapy for AML.
At a glance
| Generic name | Early receiving G-CSF group |
|---|---|
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Cytokine; Hematopoietic growth factor |
| Target | G-CSF receptor (GCSFR) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Hematology |
| Phase | FDA-approved |
Mechanism of action
G-CSF is a cytokine that binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and mobilization. Early administration of G-CSF helps prevent or mitigate chemotherapy-induced neutropenia by boosting neutrophil production before or immediately after cytotoxic treatment, reducing infection risk and allowing patients to tolerate higher chemotherapy doses.
Approved indications
- Prevention of chemotherapy-induced neutropenia in cancer patients receiving myelosuppressive chemotherapy
- Mobilization of peripheral blood progenitor cells for stem cell transplantation
Common side effects
- Bone pain
- Headache
- Fatigue
- Injection site reactions
- Splenomegaly
- Fever
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL (PHASE3)
- Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients (PHASE4)
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML (PHASE2)
- Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma (PHASE2)
- Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma (PHASE2)
- Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors (PHASE2)
- Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Early receiving G-CSF group CI brief — competitive landscape report
- Early receiving G-CSF group updates RSS · CI watch RSS
- Department of Medical Services Ministry of Public Health of Thailand portfolio CI
Frequently asked questions about Early receiving G-CSF group
What is Early receiving G-CSF group?
How does Early receiving G-CSF group work?
What is Early receiving G-CSF group used for?
Who makes Early receiving G-CSF group?
What drug class is Early receiving G-CSF group in?
What development phase is Early receiving G-CSF group in?
What are the side effects of Early receiving G-CSF group?
What does Early receiving G-CSF group target?
Related
- Drug class: All Cytokine; Hematopoietic growth factor drugs
- Target: All drugs targeting G-CSF receptor (GCSFR)
- Manufacturer: Department of Medical Services Ministry of Public Health of Thailand — full pipeline
- Therapeutic area: All drugs in Oncology; Hematology
- Indication: Drugs for Prevention of chemotherapy-induced neutropenia in cancer patients receiving myelosuppressive chemotherapy
- Indication: Drugs for Mobilization of peripheral blood progenitor cells for stem cell transplantation
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing